Key facts
- Mercy BioAnalytics’s last known valuation is $122.0M (Mar 2023).
- It has raised $127.3M across 1 recorded rounds; the latest was Early Stage VC ($27.3M) in Nov 2020.
- Notable investors include New Enterprise Associates, Jump Capital, Labcorp Venture Fund, Hatteras Venture Partners, iSelect Fund — 25 tracked in total.
- Mercy BioAnalytics has filed 1 Form D with the SEC, most recently Feb 2021 ($27.3M sold to 57 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Mercy BioAnalytics
Funding rounds
1 roundsAbout Mercy BioAnalytics
Developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detection of cancer. The company's platform interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling patients to detect various types of cancer at the earliest stages.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2018
- Employees
- 47
- Website
- mercybio.com/
- Ownership
- Privately Held (backing)
Mercy BioAnalytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mercy BioAnalytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mercy BioAnalytics in its N-PORT filings yet. We sweep new filings monthly.